CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $481,506
- in 2 filings
Net −$481,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +40,890 | 40,890 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +137,538 | 137,538 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +207,901 | 207,901 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +136,210 | 136,210 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +72,221 | 72,221 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +29,737 | 29,737 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2025-05-28 | Aurora Daljit Singh See Remarks | Grant or award · Stock Option (Right to Buy) | +1,000,000 | 1,000,000 | ||
| 2025-05-28 | Piacquad David Director | Returned to the company · Stock Option (Right to Buy) | −46,455 | 0 | ||
| 2025-05-28 | Piacquad David Director | Returned to the company · Stock Option (Right to Buy) | −28,571 | 0 | ||
| 2025-05-28 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +46,455 | 46,455 | ||
| 2025-05-28 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +28,571 | 28,571 | ||
| 2025-05-28 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −497,049 | 0 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −955,864 | 0 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −342,500 | 0 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Returned to the company · Stock Option (Right to Buy) | −2,000,000 | 0 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +497,049 | 497,049 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +955,864 | 955,864 | ||
| 2025-05-28 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +342,500 | 342,500 |
Page 6 of 20 · 384 trades